Lorch Jochen H, Klessner Jodi, Park J Ken, Getsios Spiro, Wu Yvonne L, Stack M Sharon, Green Kathleen J
Departments of Pathology and Dermatology, The Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
J Biol Chem. 2004 Aug 27;279(35):37191-200. doi: 10.1074/jbc.M405123200. Epub 2004 Jun 16.
The epidermal growth factor receptor (EGFR) has been proposed as a key modulator of cadherin-containing intercellular junctions, particularly in tumors that overexpress this tyrosine kinase. Here the EGFR tyrosine kinase inhibitor PKI166 and EGFR blocking antibody C225, both of which are used clinically to treat head and neck cancers, were used to determine the effects of EGFR inhibition on intercellular junction assembly and adhesion in oral squamous cell carcinoma cells. EGFR inhibition resulted in a transition from a fibroblastic morphology to a more epithelial phenotype in cells grown in low calcium; under these conditions cadherin-mediated cell-cell adhesion is normally reduced, and desmosomes are absent. The accumulated levels of desmoglein 2 (Dsg2) and desmocollin 2 increased 1.7-2.0-fold, and both desmosomal cadherin and plaque components were recruited to cell-cell borders. This redistribution was paralleled by an increase in Dsg2 and desmoplakin in the Triton-insoluble cell fraction, suggesting that EGFR blockade promotes desmosome assembly. Importantly, E-cadherin expression and solubility were unchanged. Furthermore, PKI166 blocked tyrosine phosphorylation of Dsg2 and plakoglobin following epidermal growth factor stimulation, whereas no change in phosphorylation was detected for E-cadherin and beta-catenin. The increase in Dsg2 protein was in part due to the inhibition of matrix metalloproteinase-dependent proteolysis of this desmosomal cadherin. These morphological and biochemical changes were accompanied by an increase in intercellular adhesion based on functional assays at all calcium concentrations tested. Our results suggest that EGFR inhibition promotes desmosome assembly in oral squamous cell carcinoma cells, resulting in increased cell-cell adhesion.
表皮生长因子受体(EGFR)被认为是含钙黏着蛋白的细胞间连接的关键调节因子,尤其是在过表达这种酪氨酸激酶的肿瘤中。本文使用临床上用于治疗头颈癌的EGFR酪氨酸激酶抑制剂PKI166和EGFR阻断抗体C225,来确定EGFR抑制对口腔鳞状细胞癌细胞间连接组装和黏附的影响。EGFR抑制导致在低钙条件下生长的细胞从成纤维细胞形态转变为更上皮样的表型;在这些条件下,钙黏着蛋白介导的细胞间黏附通常会降低,并且不存在桥粒。桥粒芯糖蛋白2(Dsg2)和桥粒胶蛋白2的累积水平增加了1.7至2.0倍,并且桥粒钙黏着蛋白和斑块成分都被募集到细胞间边界。这种重新分布与Triton不溶性细胞组分中Dsg2和桥粒斑蛋白的增加平行,表明EGFR阻断促进桥粒组装。重要的是,E-钙黏着蛋白的表达和溶解性没有变化。此外,PKI166阻断了表皮生长因子刺激后Dsg2和桥粒斑珠蛋白的酪氨酸磷酸化,而未检测到E-钙黏着蛋白和β-连环蛋白的磷酸化变化。Dsg2蛋白的增加部分归因于这种桥粒钙黏着蛋白的基质金属蛋白酶依赖性蛋白水解的抑制。在所有测试的钙浓度下,基于功能测定,这些形态学和生化变化伴随着细胞间黏附的增加。我们的结果表明,EGFR抑制促进口腔鳞状细胞癌细胞中的桥粒组装,导致细胞间黏附增加。